reuters has a strong buy on psivida

Reuters and Charles Schwab and CO. has put a stong buy on the shares with targey short to medium term of $12. As soon as the street catches on I think we will get a move quickly to $8-9.Next years eps estimate is 56 cents. There are 500,000-1,000,000 with DME which is the malady addressed By Psividas lead product Iluvien. The market size is huge and the market cap of Psivida is tiny which are all the ingredients for a 10 bagger. Pfizer owns 10% of Psivida and could buy company in a flash for $12 as there are 153 million in other royalty payments due Psivisa from Pfizer, so it would be cheaper to buy Psivida than pay Psivida. I added some shares last week and will do so this week too.